Abstract-Platelet aggregation is inhibited through a negative feedback mechanism by the L-arginine/nitric oxide (NO) pathway found in platelets themselves. We have shown that long-term smoking impairs the bioactivity of platelet-derived NO (PDNO), resulting in an increased platelet aggregability. However, little is known about the relation between other coronary risk factors and PDNO release. Accordingly, this study was undertaken to examine whether other coronary risk factors are related to the impairment of PDNO bioactivity. We measured collagen-induced PDNO release with an NO-selective electrode in 61 subjects (mean age 47 years, range 24 to 74 years) who underwent complete physical and laboratory examinations. There was a significant inverse correlation between PDNO release and the number of coronary risk factors (rϭϪ0. Key Words: platelets Ⅲ nitric oxide Ⅲ risk factors Ⅲ atherothrombosis P latelets possess the functional L-arginine/nitric oxide (NO) pathway via constitutive NO synthase. 1,2 Platelet-derived NO (PDNO) increases the intraplatelet level of cGMP and inhibits platelet aggregation. 1 This modulation of platelet aggregation via the L-arginine/NO pathway is recognized as a negative-feedback mechanism to inhibit aggregation. 3, 4 Using an NO-selective electrode, we 5 and others 6 directly measured PDNO release during platelet aggregation, which was potentiated by L-arginine and attenuated by inhibitors of NO synthase, indicating the existence of an L-arginine/NO pathway in human platelets. 1,7 PDNO has been shown to play a functional role in the inhibition of not only platelet activation but also platelet recruitment after aggregation. 8 Recently, we have shown that long-term smoking impairs PDNO release, resulting in an increased platelet aggregability. 5 However, little is known about the relation between other coronary risk factors and PDNO release. Accordingly, the present study was undertaken to investigate the hypothesis that other coronary risk factors impair platelet function and thereby affect PDNO release in subjects with major risk factors.
P latelets possess the functional L-arginine/nitric oxide (NO) pathway via constitutive NO synthase. 1, 2 Platelet-derived NO (PDNO) increases the intraplatelet level of cGMP and inhibits platelet aggregation. 1 This modulation of platelet aggregation via the L-arginine/NO pathway is recognized as a negative-feedback mechanism to inhibit aggregation. 3, 4 Using an NO-selective electrode, we 5 and others 6 directly measured PDNO release during platelet aggregation, which was potentiated by L-arginine and attenuated by inhibitors of NO synthase, indicating the existence of an L-arginine/NO pathway in human platelets. 1, 7 PDNO has been shown to play a functional role in the inhibition of not only platelet activation but also platelet recruitment after aggregation. 8 Recently, we have shown that long-term smoking impairs PDNO release, resulting in an increased platelet aggregability. 5 However, little is known about the relation between other coronary risk factors and PDNO release. Accordingly, the present study was undertaken to investigate the hypothesis that other coronary risk factors impair platelet function and thereby affect PDNO release in subjects with major risk factors.
Methods

Study Subjects
The study population consisted of 61 subjects who agreed to participate in the study. The subjects underwent complete routine physical and laboratory examinations, and their complete anamnesis was obtained. Of the 61 subjects, 42 were healthy volunteers, 12 had stable effort angina, and 7 had previous myocardial infarction. Medications, including long-acting nitrates, calcium channel blockers, ␤-blockers, and ACE inhibitors, were withheld for Ն24 hours, and aspirin was withheld for Ն1 week before the study. None of the patients had received cholesterol-lowering agents. Patients with acute coronary syndromes, valvular heart diseases, or heart failure were excluded from the study. The present protocol was approved by our institutional ethic committee, and informed consent for the study was obtained from all patients.
Definition of Coronary Risk Factors
Coronary risk factors in this study were determined according to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure report. 9 Hypertension was defined as a systolic blood pressure of Ն140 mm Hg, a diastolic blood pressure of Ն90 mm Hg, or both. Hypercholesterolemia was defined as a total serum cholesterol level Ն220 mg/dL, which was measured with an enzymatic method. None of the patients had documented familial hyperlipidemia. Subjects who smoked Ն15 cigarettes per day for Ն5 years were considered to be long-term smokers. Long -term smokers were asked to abstain from smoking for Ն120 minutes before the study to avoid the acute effects of smoking on platelet function. Family history was considered positive if a first-degree relative had clinical evidence of coronary artery disease (angina pectoris or myocardial infarction) at the age of Յ60 years. None of the patients had a history of insulin-dependent diabetes mellitus or elevated blood glucose. A composite risk factor score was calculated for each subject, with 1 point given for each of the following: age of Ͼ60 years, current smoker, hypertension, hypercholesterolemia, and family history of coronary artery disease.
Preparation of Washed Platelets
Platelet suspensions were prepared according to a previously described method. 5, 10 Briefly, 20 mL of blood from all subjects was collected through venipuncture into a plastic tube containing 3.15% trisodium citrate (1:9 v/v) and prostacyclin (2 g/mL; Sigma Chemical Co) and then centrifuged at 250g for 20 minutes at 22°C. The obtained supernatant, platelet-rich plasma, was centrifuged again at 900g for 10 minutes at 22°C after the addition of prostacyclin (300 ng/mL). The platelet pellet was resuspended in 5 mL of Ca 2ϩ and Mg 2ϩ -free Tyrode's solution (pH 7.4) containing prostacyclin (300 ng/mL) and centrifuged at 800g for 10 minutes at 37°C. 
Measurements of PDNO With an NO-Specific Electrode
We measured PDNO with an NO meter (model N0-501; Inter Medical Co) that measures the picoampere-order redox current between the working electrode and the counterelectrode, as previously described. 5 Briefly, the working electrode consisted of a platinum/iridium alloy wire (OD 0.2 mm) coated with a 3-layer membrane that included the KCl membrane, NO-selective resin, and normal silicone membrane. The counterelectrode was made of carbon fiber (OD 0.5 mm). 11 The NO meter and electrodes were placed into an electromagnetic shield box to avoid the electrical perturbation of the electrodes. The two electrodes were placed in a chamber containing washed platelet suspensions. After the addition of collagen (3 g/mL), the working electrode was supplied with ϩ0.6 V for the electrochemical oxidation of NO diffusing through the membrane to avoid currents from possible contaminants of oxygen because electrode responses to oxygen changes were observed at voltages of Ͻϩ0.4 V. 11, 12 The obtained electrical current was considered to be an index of NO release.
Statistical Analysis
Data are expressed as meanϮSD. The number of risk factors was considered a continuous variable and compared with PDNO release with linear regression analysis. Repeated measures ANOVA was applied for multiple comparisons. Univariate analysis of the effects of each risk on PDNO release was performed with linear regression for continuous variables (age; systolic, diastolic, and mean blood pressures; and total, HDL-, and LDL-cholesterol levels) and 1-way ANOVA for categorical variables (gender, smoking, family history of coronary artery disease, evidence of coronary artery disease). Then, the interaction between various risk characteristics and PDNO release was examined with multiple stepwise regression analysis. Statistical significance was considered at the level of PϽ0.05.
Results
Clinical Characteristics of the Subjects
The subjects consisted of 52 men and 9 women (30 nonsmokers and 31 smokers, mean age 47 years, range 24 to 74 years).
The averaged systolic, diastolic, and mean arterial pressures were 127Ϯ15, 76Ϯ10, and 93Ϯ10 mm Hg, respectively; 15 subjects had hypertension. Five subjects had a positive family history of coronary artery disease. The average levels of total, HDL-, and LDL-cholesterol and triglycerides were 192Ϯ27, 118Ϯ27, 48Ϯ13, and 128Ϯ56 mg/dL, respectively; 12 subjects had hypercholesterolemia.
PDNO and Coronary Risk Factors
Mean PDNO was 9.6Ϯ4 pA (range 3.5 to 22 pA). The mean number of risk factors was 1.4Ϯ1.1, and the composite risk factor was 0 in 17, 1 in 17, 2 in 17, 3 in 8, and 4 in 2 subjects. PDNO release was significantly lower in subjects with risk factors (8.3Ϯ2.4, 8.9Ϯ2.7, 6.4Ϯ3.1, and 4.5Ϯ0.7 pA for subjects with 1, 2, 3, and 4 risk factors, respectively) than in subjects without risk factors (13.6Ϯ3.6 pA) (PϽ0.05). PDNO release exhibited a significant inverse correlation with the number of risk factors (rϭϪ0.61, PϽ0.001; Figure 1 ). Univariate analysis showed a significant inverse correlation between PDNO release and age (rϭϪ0.33, PϽ0.01; Figure  2A ), systolic blood pressure (rϭϪ0.38, PϽ0.005), diastolic blood pressure (rϭϪ0.34, PϽ0.01), mean arterial pressure (rϭϪ0.40, PϽ0.01; Figure 2B ), total cholesterol level (rϭϪ0.31, PϽ0.02; Figure 2C ), and LDL-cholesterol level (rϭϪ0.33, PϽ0.02). PDNO release did not correlate with triglycerides or HDL-cholesterol levels. PDNO release was significantly lower in smokers than in nonsmokers (PϽ0.001; Figure 2D ) and significantly lower in subjects with coronary artery disease than in healthy volunteers (10.3Ϯ4.1 versus 8.0Ϯ3.1 pA, PϽ0.05). However, neither gender nor family history of coronary artery disease seemed to affect PDNO release. Multiple stepwise regression analysis ( Table) revealed that PDNO release significantly and independently (r 2 ϭ0.51) correlated with smoking, age, and mean arterial pressure.
Discussion
In the present study, the most important findings were that (1) the significant inverse correlation was found between PDNO release and the number of risk factors and that (2) PDNO release independently correlated with smoking, aging, and hypertension. Thus, our findings suggest that impairment of PDNO release by platelets is associated with coronary risk factors in humans.
It has been shown that an NO-selective electrode is specifically capable of measuring real-time release of NO from endothelial cells 11, 13, 14 and platelets. 6, 15 We also previously showed that the electrode used in this study was sufficiently sensitive to detect the release of NO from aggregated platelets on the basis of the following findings. 5 First, S-nitroso-N-acetyl-dl-penicillamine, a direct NO donor, dose-dependently increased the electrical current. Second, the electrical current showed a high correlation with collagen concentrations from 1 to 5 g/mL (rϭ0.94). Third, the collagen-induced electrical current and intraplatelet levels of cGMP were increased by L-arginine and attenuated by N G -monomethyl-L-arginine, an inhibitor of NO synthesis. Fourth, a good correlation was found between collagen-induced intraplatelet cGMP and the electrical current (rϭ0.73). Thus, we confirmed that the changes in the electrical current reflect the amount of NO released through the L-arginine/NO pathway in aggregated platelets.
We previously reported that long-term smoking impairs PDNO release. 5 The same findings were obtained in this study. We further examined whether other major risk factors are associated with impaired PDNO release during platelet aggregation. A significant inverse correlation was observed between PDNO release and the number of risk factors. Univariate analysis showed that PDNO release was inversely related to risk factors such as aging, hypertension, and hypercholesterolemia. Thus, our findings suggest not only that individual risk factors impair PDNO release but also that PDNO release is further impaired when the number of risk factors increases. When the multiple stepwise regression model was used to predict PDNO release with age, gender, cholesterol level, blood pressure, smoking, and family history as independent variables, PDNO release was found to be independently related to smoking, aging, and hypertension. Most importantly, PDNO release showed the strongest negative correlation with smoking. Accordingly, among major risk factors, smoking is the most powerful factors affecting PDNO release. Taken together, our findings may suggest that the L-arginine/NO pathway, as a negative feedback mechanism to inhibit platelet aggregation, is impaired in subjects with major risk factors, leading to an increased platelet aggregability and the development of atherothrombotic disease.
In the present study, the presence of coronary risk factors was associated with an impairment of PDNO release in human platelets. These risk factors have been shown to impair endothelium-dependent vasodilation 16 -18 and to reduce bioactivity of NO 19 in the human coronary arteries. On the bases of the present and other studies, coronary risk factors may impair the L-arginine/NO pathway in both endothelial cells and platelets. Epidemiological studies have demonstrated that exposure to multiple risk factors increases the occurrence of atherosclerosis and thrombosis. 20 -22 Because endogenous NO has antiatherothrombotic actions, 8, 23 our findings may contribute to an understanding of the pathophysiological link between risk factors and atherothrombotic disease.
The correlations between each risk factor and PDNO release in this study were relatively weak. A possible reason is that the present study included a relatively small number of subjects compared with epidemiological trials. Hence, it is possible that a significant independent correlation between PDNO release and other risk factors, such as hypercholesterolemia, diabetes mellitus, or family history, would be shown in a larger sample size. In this study, the r 2 value for the multiple stepwise regression model of PDNO release with all independent variables was 0.51, implying that 51% of the variability of PDNO release could be explained by the risk factors. Finally, we were unable to determine with our method whether coronary risk factors impair the release of PDNO or increase the inactivation of PDNO released from platelets.
In conclusion, the present study demonstrates that coronary risk factors are associated with an impairment of PDNO release in human platelets.
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